Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort

References

• Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2–10.
   PubMed Web of Science ®Google Scholar
• Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;8:139–53.
   Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940–4.
   PubMed Web of Science ®Google Scholar
• Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269–77.
   PubMed Web of Science ®Google Scholar
• Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29:335–49, vii.
   PubMed Web of Science ®Google Scholar
• Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344–50.
   PubMed Web of Science ®Google Scholar
• Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892–6.
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493–537.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284–91.
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151–7.
   PubMed Web of Science ®Google Scholar
• Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35:458–65.
   PubMed Web of Science ®Google Scholar
• Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005;32:1273–8.
   PubMedGoogle Scholar
• York M, Farber HW. Pulmonary hypertension: screening and evaluation in scleroderma. Curr Opin Rheumatol 2011;23:536–44.
   PubMed Web of Science ®Google Scholar
• Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088–93.
   PubMed Web of Science ®Google Scholar
• Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792–800.
   PubMed Web of Science ®Google Scholar
• Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011;63:3522–30.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012;64:1257–62.
   PubMed Web of Science ®Google Scholar
• Meune C, Vignaux O, Kahan A, Allanore Y. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010;103:46–52.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008;20:697–702.
   PubMedGoogle Scholar
• Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009;60:1831–9.
   PubMed Web of Science ®Google Scholar
• Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;8:154–67.
   Google Scholar
• Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062–76.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010;12:484–91.
   PubMed Web of Science ®Google Scholar
• Elmas E, Doesch C, Fluechter S, Freundt M, Weiss C, Lang S, Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Int J Cardiovasc Imaging 2011;27:547–56.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
   PubMed Web of Science ®Google Scholar
• Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902–12.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441–7.
   PubMed Web of Science ®Google Scholar
• Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336–40.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010;37:105–15.
   PubMedGoogle Scholar
• Saggar R, Sitbon O. Hemodynamics in pulmonary arterial hypertension: current and future perspectives. Am J Cardiol 2012;110(Suppl):S9–15.
   Google Scholar
• Bossone E, Naeije R. Exercise-induced pulmonary hypertension. Heart Fail Clin 2012;8:485–95.
   PubMed Web of Science ®Google Scholar
• Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000;162:1964–73.
   PubMedGoogle Scholar
• Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539–42.
   PubMed Web of Science ®Google Scholar
• Miguel D, Prieto B, Costa M, Coto D, Alvarez FV. Cord blood plasma reference intervals for potential sepsis markers: pro-adrenomedullin, pro-endothelin, and pro-atrial natriuretic peptide. Clin Biochem 2011;44:337–41.
   PubMed Web of Science ®Google Scholar
• Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009;42:725–8.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Wahbi K, Borderie D, Weber S, Kahan A, Meune C. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 2009;68:1885–9.
   PubMedGoogle Scholar
• Dimitroulas T, Giannakoulas G, Karvounis H, Gatzoulis MA, Settas L. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 2010;39:278–84.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Giannakoulas G, Papadopoulou K, Karvounis H, Dimitroula H, Koliakos G, Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 2010;37:993–9.
   PubMed Web of Science ®Google Scholar
• Chatterjee S. Pulmonary hypertension in systemic sclerosis. Semin Arthritis Rheum 2011;41:19–37.
   PubMed Web of Science ®Google Scholar
• Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D, N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 2012;14:R143.
   PubMed Web of Science ®Google Scholar
• Chighizola C, Meroni PL, Schreiber BE, Coghlan JG, Denton CP, Ong VH. Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. Clin Exp Rheumatol 2012;30(Suppl 71):S81–5.
   Google Scholar
• Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824–39.
   PubMed Web of Science ®Google Scholar
• Desai CS, Lee DC, Shah SJ. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol 2011;23:545–54.
   PubMed Web of Science ®Google Scholar
• Potocki M, Ziller R, Mueller C. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? Curr Heart Fail Rep 2012;9:244–51.
   PubMedGoogle Scholar
• Kazzam E, Caidahl K, Hedner T, Waldenstrom A. Functional explanation for increased atrial natriuretic peptide in systemic sclerosis. Clin Cardiol 1995;18:647–52.
   PubMedGoogle Scholar
• Mok MY, Cheung BM, Lo Y, Leung RY, Wong WS, Lau CS. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis. J Rheumatol 2007;34:2224–9.
   PubMedGoogle Scholar
• Tzelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C, Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007;56:3827–36.
   PubMed Web of Science ®Google Scholar
• Hachulla AL, Launay D, Gaxotte V, de Groote P, Lamblin N, Devos P, Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878–84.
   PubMed Web of Science ®Google Scholar
• Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008;52:1574–80.
   PubMed Web of Science ®Google Scholar
• Messroghli DR, Greiser A, Frohlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007;26:1081–6.
   PubMed Web of Science ®Google Scholar
• Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003;9:311–17.
   PubMed Web of Science ®Google Scholar
• Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F, Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum 2005;34: 721–7.
   PubMed Web of Science ®Google Scholar
• de Groote P, Gressin V, Hachulla E, Carpentier P, Guillevin L, Kahan A, Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008;67:31–6.
   PubMed Web of Science ®Google Scholar
• Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008;58:1803–9.
   PubMed Web of Science ®Google Scholar
• Vohringer M, Mahrholdt H, Yilmaz A, Sechtem U. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR). Herz 2007;32:129–37.
   PubMedGoogle Scholar
• Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson 2011;13:16.
   PubMed Web of Science ®Google Scholar
• Chartrand S, Miller L, Koenig M, Goulet JR, Rich É, Chin AS, Measurement of pulmonary arteries by cardiac magnetic resonance imaging: a simple and useful tool for the detection of pulmonary hypertension in systemic sclerosis patients without overt microvascular perfusion defects or fibrosis. Arthritis Rheum 2012;64(Suppl 10):S309.
   Google Scholar
• Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010;37:2290–8.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250–94.
   Google Scholar
• Kovacs G, Maier R, Aberer E, Brodmann M, Scheidl S, Troster N, Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med 2009;180:881–6.
   PubMed Web of Science ®Google Scholar
• Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J 2013;42: 1083–91.
   PubMed Web of Science ®Google Scholar